A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II study designed to study the effectiveness of combined radiotherapy and
erlotinib in the postoperative setting for patients with cutaneous SCC that are at high risk
for recurrence. Participants enrolled in the study will be evaluated by a head and neck
surgeon, and a radiation oncologist. Whenever possible, a preoperative biopsy will be
performed after participant enrollment in the study for histological confirmation and for
molecular correlates. Participants enrolled prior to surgical resection will begin erlotinib
at 150 mg by mouth (PO) every day (QD) (14 tablets) to be taken 14 days prior to surgical
resection. Following planned surgical resection, the participant will begin Erlotinib therapy
and radiotherapy at the same time and within 4-8 weeks of the surgical resection.